Cue Biopharma
About: Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Employees: 41
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
488% more call options, than puts
Call options by funds: $47K | Put options by funds: $8K
280% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 5
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
22% more capital invested
Capital invested by funds: $10.5M [Q3] → $12.8M (+$2.28M) [Q4]
8% more funds holding
Funds holding: 50 [Q3] → 54 (+4) [Q4]
10.04% less ownership
Funds ownership: 28.6% [Q3] → 18.56% (-10.04%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Citizens Capital Markets Reni Benjamin 20% 1-year accuracy 8 / 40 met price target | 155%upside $2 | Market Outperform Reiterated | 2 Apr 2025 |
Financial journalist opinion
Based on 8 articles about CUE published over the past 30 days









